NCT07182981

Brief Summary

It is recommended to focus on the physical functionality, chewing, and swallowing performance of individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. The aim was to assess the biopsychosocial characteristics of both children and adults diagnosed with scleroderma and to examine their chewing and swallowing performance. Additionally, this study aims to identify effective scales that can be used in future research to assess chewing and swallowing in individuals diagnosed with scleroderma.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
15mo left

Started Aug 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress38%
Aug 2025Aug 2027

Study Start

First participant enrolled

August 4, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 13, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 19, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2027

Expected
3 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 4, 2027

Last Updated

September 19, 2025

Status Verified

August 1, 2025

Enrollment Period

2 years

First QC Date

September 13, 2025

Last Update Submit

September 13, 2025

Conditions

Keywords

Juvenile sclerodermasclerodermasystemic sclerosis

Outcome Measures

Primary Outcomes (7)

  • Pediatric Eating Assessment Scale (PEDI-EAT-10)

    It is used to evaluate swallowing disorders in pediatric patients. It was developed as the pediatric version of the EAT-10, which is used in adults. The PEDI-EAT-10 comprises 10 questions, each with a Likert scale ranging from 0 to 4 (0 = no problem, 4 = severe problem). The total score is calculated out of 40 points.

    Two weeks

  • Chewing and Swallowing Test for Children (TOMASS-C)

    It is a measurement tool developed specifically for children to assess chewing performance. TOMASS-C is a standardized method that quantitatively evaluates the chewing and swallowing of a solid food (cracker) in the pediatric population. During the test, the following parameters will be observed and recorded: * Number of bites * Number of chewing cycles * Number of swallows * Task completion time (in seconds)

    Two weeks

  • 3-Ounce Water Swallow Challenge

    It is a commonly used method for assessing oropharyngeal dysphagia and aspiration risk. Subjects must swallow 3 ounces (90 cc) of water without interruption. Failure to complete the task, coughing, choking, or exhibiting a wet-gurgling voice quality within 1 minute during or after the test is included. Subjects who can drink 90 cc of water completely and in one go without coughing, choking, or drinking the water in portions have completed the test.

    Two weeks

  • Turkish Eating Assessment Tool (T-EAT-10)

    It is a questionnaire consisting of 10 questions with a Likert scale ranging from 0 to 4 (0 = no problem, 4 = severe problem). The total score is calculated out of 40 points by summing the responses given to each question. A score of 3 or higher is considered abnormal in the questionnaire.

    Two weeks

  • Test of Masticating and Swallowing Solids (TOMASS)

    The test evaluates how many bites it takes an individual to eat a biscuit while sitting upright, how many chewing cycles they perform, how many times they swallow, and the total time from bite to swallow. The number of bites, number of chewing cycles, number of swallows, and total time will be calculated.

    Two weeks

  • Maximum Mouth Opening (MMO)

    After ensuring that individuals open their mouths as wide as possible, the distance between the incisal edges of the central incisors in the upper and lower jaws will be measured in millimeters using a ruler, and the values will be recorded.

    Two weeks

  • Dysphagia Limit (DL)

    Individuals are given liquids in volumes of 5, 10, 15, 20, 25, 30, 35, 40, and 45 mL using a graduated syringe, and they are asked to swallow the liquid. The maximum amount of liquid that can be swallowed during a single movement of the thyroid cartilage is determined. In healthy individuals, the normal dysphagia limit is more than 20 mL. If a person can normally swallow 20 mL, the dysphagia limit is considered normal.

    Two weeks

Secondary Outcomes (16)

  • Modified Rodnan skin score (MRSS)

    Two weeks

  • Localized Scleroderma Assessment Tool (LoSCAT)

    Two weeks

  • Mouth Handicap in Systemic Sclerosis Questionnaire (MHIIS)

    Two weeks

  • Fonseca Anamnestic Questionnaire

    Two weeks

  • Modified Hand Mobility in Scleroderma Test (mHAMIS)

    Two weeks

  • +11 more secondary outcomes

Study Arms (1)

Cases diagnosed with scleroderma

Child and adult scleroderma patients who visited the rheumatology outpatient clinic at a university hospital will complete a questionnaire.

Other: Questionnaire application for child and adult scleroderma patients

Interventions

Scales will be applied to cases diagnosed with scleroderma

Cases diagnosed with scleroderma

Eligibility Criteria

Age7 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population will consist of individuals who come to the university hospital for routine controls.

You may qualify if:

  • Cases diagnosed with scleroderma,
  • Cases aged 7-18 years will be included.

You may not qualify if:

  • Advanced heart/lung/liver/kidney disease, neurological disease, and malignancies
  • Cases that are not willing to participate in the study will be excluded.
  • Having participated in a regular exercise program for the past 3 months
  • Individuals who are not willing to participate in the study
  • For adults diagnosed with scleroderma:
  • Individuals diagnosed with scleroderma,
  • Individuals over the age of 18 will be included.
  • Advanced heart/lung/liver/kidney disease, neurological disease, and malignancies
  • Individuals who are not willing to participate in the study will be excluded.
  • Having participated in a regular exercise program for the past 3 months
  • Individuals who are not willing to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hacettepe University

Çankaya, Ankara, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Scleroderma, SystemicScleroderma, DiffuseScleroderma, LocalizedJuvenile-onset scleroderma

Condition Hierarchy (Ancestors)

Connective Tissue DiseasesSkin and Connective Tissue DiseasesSkin Diseases

Central Study Contacts

Orkun Tüfekçi, PT, PhD(c)

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Weeks
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, PT, PhD(c)

Study Record Dates

First Submitted

September 13, 2025

First Posted

September 19, 2025

Study Start

August 4, 2025

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

August 4, 2027

Last Updated

September 19, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations